Peng brings a wide range of experience across biotech, finance, and law to his role as CEO of Conscience. He is the founder of Novatio Ventures, an investment and advisory firm focused on accelerating the commercialization of early-stage life science innovations and providing tailored financing solutions to growth-stage companies. He is also a board member and founding investor of 3io Therapeutics and Precision Proteomics, two Canadian companies developing technologies licensed from academic institutions.
Previously, Peng was Managing Director and Partner at CBC Group and LYFE Capital, two global healthcare private equity firms. He has also held senior roles at DRI Capital (now DRI Healthcare), Amgen Canada, and Teva Pharmaceuticals. Peng began his career as a life sciences attorney in private practice at Torys and Gilbert’s LLP in Toronto. He holds an MSc in biology from the University of Toronto and a JD from Queen’s University.
